全球减肥药龙头，股价暴跌

Core Viewpoint - The company has lowered its 2025 outlook, expecting a sales growth of 8%-14% at constant exchange rates, down from a previous expectation of 13%-21% [1] Group 1 - The reduced growth forecast is attributed to lower growth expectations for Wegovy in the U.S. obesity market [1] - The growth expectations for Ozempic in the U.S. GLP-1 diabetes market have also been lowered [1] - Wegovy's penetration in certain IO markets is below expectations [1]